Coherus (CHRS) CFO awarded 112,500 RSUs and 225,000 options

Rhea-AI Filing Summary

Coherus Oncology, Inc.’s Chief Financial Officer, Bryan J. McMichael, reported new equity awards. On January 22, 2026, he received 112,500 restricted stock units of common stock at $0 per share, bringing his directly held common stock to 133,736 shares. These RSUs vest in two equal parts, with 50% vesting on May 20, 2027 and 50% on March 20, 2029, subject to continued service. He was also granted a stock option for 225,000 shares of common stock at an exercise price of $1.59 per share, all held directly. The option vests 25% on the one-year anniversary of January 22, 2026, and the remainder in equal monthly installments over the following three years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMichael Bryan J

(Last) (First) (Middle)

C/O COHERUS ONCOLOGY, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		112,500(1)	A	$0	133,736	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.59	01/22/2026		A		225,000		(2)	01/22/2036	Common Stock	225,000	$0	225,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest on May 20, 2027 and 50% of the RSUs vest on March 20, 2029, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

2. The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 22, 2026 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

	/s/ Bryan J. McMichael	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did the Coherus (CHRS) CFO report on this Form 4?

The Coherus Oncology, Inc. Chief Financial Officer, Bryan J. McMichael, reported receiving 112,500 restricted stock units (RSUs) of common stock and a stock option for 225,000 shares of common stock.

What are the vesting terms for Bryan McMichael’s 112,500 RSUs at Coherus (CHRS)?

The 112,500 RSUs vest in two tranches: 50% vest on May 20, 2027, and the remaining 50% vest on March 20, 2029, subject to his continued service with Coherus Oncology, Inc. on each vesting date.

What are the key terms of the 225,000 stock options granted to the Coherus (CHRS) CFO?

The CFO received a stock option for 225,000 shares of Coherus common stock with an exercise price of $1.59 per share. The option vests as to 1/4 of the total shares on the one-year anniversary of January 22, 2026, and 1/48 of the total shares in equal monthly installments thereafter, subject to continued service, and expires on January 22, 2036.

How many Coherus (CHRS) common shares does the CFO own after these RSU grants?

Following the reported RSU transaction, Bryan J. McMichael beneficially owns 133,736 shares of Coherus Oncology, Inc. common stock directly.

Were these Coherus (CHRS) insider transactions purchases or grants?

Both reported transactions are grants. The Form 4 shows transaction code “A” (acquired) for the 112,500 RSUs and for the 225,000 stock options, each at a transaction price of $0 per security.

What is Bryan McMichael’s role and relationship to Coherus (CHRS)?

Bryan J. McMichael is reported as an officer of Coherus Oncology, Inc., serving as its Chief Financial Officer, and he is not listed as a director or 10% owner.